Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
2019 · New England Journal of Medicine · 2,755 citations
https://doi.org/10.1056/nejmoa1910231
R
Reyes Bernabé
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
200
Papers
12.9K
Citations
34
h-index
74
i10-index
Reyes Bernabé is an academic researcher from Hospital Universitario Virgen del Rocío. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Cancer Immunotherapy and Biomarkers. The author has an h-index of 34, co-authored 170 publications.
ORCID: 0000-0003-0312-9195Papers by this author
worksNeoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
2020 · The Lancet Oncology · 788 citations
https://doi.org/10.1016/s1470-2045(20)30453-8
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
2022 · Journal of Clinical Oncology · 327 citations
https://doi.org/10.1200/jco.21.02660
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
2021 · Journal of Thoracic Oncology · 318 citations
https://doi.org/10.1016/j.jtho.2021.09.010
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
2021 · Annals of Oncology · 111 citations
https://doi.org/10.1016/j.annonc.2021.11.010
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
2021 · Annals of Oncology · 111 citations
https://doi.org/10.1016/j.annonc.2021.11.010
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat